Sort   by:  
 Page size 
UnknownMolecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Not available
S-EPMC4980567 | biostudies-literature
UnknownEffect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Not available
S-EPMC7058271 | biostudies-literature
UnknownKCTD7 deficiency defines a distinct neurodegenerative disorder with a conserved autophagy-lysosome defect.
Not available
S-EPMC6295419 | biostudies-literature
UnknownNeoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Not available
S-EPMC10956403 | biostudies-literature
UnknownNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Not available
S-EPMC8571284 | biostudies-literature
UnknownAdaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Not available
S-EPMC5259561 | biostudies-literature
UnknownAdaptive Randomization of Neratinib in Early Breast Cancer.
Not available
S-EPMC5259558 | biostudies-literature
UnknownTransforming the future of health together: The Learning Health Systems Consensus Action Plan.
Not available
S-EPMC6508804 | biostudies-literature
UnknownPredicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Not available
S-EPMC7695723 | biostudies-literature
UnknownLate Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators: A 2-Year Cohort Analysis.
Not available
S-EPMC10442778 | biostudies-literature
Sort   by:  
 Page size